The influence of BRCA2 mutation on localized prostate cancer

Renea A. Taylor, Michael Fraser, Richard J. Rebello, Paul C. Boutros, Declan G. Murphy, Robert G. Bristow, Gail P. Risbridger

Research output: Contribution to journalReview ArticleResearchpeer-review

3 Citations (Scopus)

Abstract

A key challenge in the management of localized prostate cancer is the identification of men with a high likelihood of progression to an advanced, incurable stage. Patients who harbour germline BRCA2 mutations have worse clinical outcomes than noncarriers when treated with surgery or radiotherapy. Insights from different disciplines have improved our understanding of why patients with BRCA2-mutant tumours have a high likelihood of failing on conventional management after diagnosis. Treatment-naive BRCA2-mutant tumours are defined by aggressive clinical and molecular features early in the disease course, and the genomic landscape of these BRCA2-mutant tumours is characterized by a unique molecular profile and higher genomic instability than noncarrier tumours. Moreover, BRCA2-mutant tumours commonly show the concurrent presence of the intraductal carcinoma of the prostate (IDCP) pathology, a poor prognostic indicator. Subclonal analyses have revealed that IDCP and invasive adenocarcinoma in BRCA2-mutant tumours can arise from the same ancestral clone, implying that a temporal evolutionary trajectory exists. Finally, functional studies have shown that BRCA2-mutant tumours can harbour a subpopulation of cancer cells that can tolerate castration de novo, enabling the tumour to evade androgen deprivation therapy. Importantly, future challenges remain regarding how to best model the biology underpinning this aggressive phenotype and translate these findings to improve clinical outcomes.

Original languageEnglish
Pages (from-to)281-290
Number of pages10
JournalNature Reviews Urology
Volume16
Issue number5
DOIs
Publication statusPublished - 1 May 2019

Cite this

Taylor, Renea A. ; Fraser, Michael ; Rebello, Richard J. ; Boutros, Paul C. ; Murphy, Declan G. ; Bristow, Robert G. ; Risbridger, Gail P. / The influence of BRCA2 mutation on localized prostate cancer. In: Nature Reviews Urology. 2019 ; Vol. 16, No. 5. pp. 281-290.
@article{751cc3016ccc4d6ea2a0aea9ab40eba3,
title = "The influence of BRCA2 mutation on localized prostate cancer",
abstract = "A key challenge in the management of localized prostate cancer is the identification of men with a high likelihood of progression to an advanced, incurable stage. Patients who harbour germline BRCA2 mutations have worse clinical outcomes than noncarriers when treated with surgery or radiotherapy. Insights from different disciplines have improved our understanding of why patients with BRCA2-mutant tumours have a high likelihood of failing on conventional management after diagnosis. Treatment-naive BRCA2-mutant tumours are defined by aggressive clinical and molecular features early in the disease course, and the genomic landscape of these BRCA2-mutant tumours is characterized by a unique molecular profile and higher genomic instability than noncarrier tumours. Moreover, BRCA2-mutant tumours commonly show the concurrent presence of the intraductal carcinoma of the prostate (IDCP) pathology, a poor prognostic indicator. Subclonal analyses have revealed that IDCP and invasive adenocarcinoma in BRCA2-mutant tumours can arise from the same ancestral clone, implying that a temporal evolutionary trajectory exists. Finally, functional studies have shown that BRCA2-mutant tumours can harbour a subpopulation of cancer cells that can tolerate castration de novo, enabling the tumour to evade androgen deprivation therapy. Importantly, future challenges remain regarding how to best model the biology underpinning this aggressive phenotype and translate these findings to improve clinical outcomes.",
author = "Taylor, {Renea A.} and Michael Fraser and Rebello, {Richard J.} and Boutros, {Paul C.} and Murphy, {Declan G.} and Bristow, {Robert G.} and Risbridger, {Gail P.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1038/s41585-019-0164-8",
language = "English",
volume = "16",
pages = "281--290",
journal = "Nature Clinical Practice Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "5",

}

Taylor, RA, Fraser, M, Rebello, RJ, Boutros, PC, Murphy, DG, Bristow, RG & Risbridger, GP 2019, 'The influence of BRCA2 mutation on localized prostate cancer', Nature Reviews Urology, vol. 16, no. 5, pp. 281-290. https://doi.org/10.1038/s41585-019-0164-8

The influence of BRCA2 mutation on localized prostate cancer. / Taylor, Renea A.; Fraser, Michael; Rebello, Richard J.; Boutros, Paul C.; Murphy, Declan G.; Bristow, Robert G.; Risbridger, Gail P.

In: Nature Reviews Urology, Vol. 16, No. 5, 01.05.2019, p. 281-290.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - The influence of BRCA2 mutation on localized prostate cancer

AU - Taylor, Renea A.

AU - Fraser, Michael

AU - Rebello, Richard J.

AU - Boutros, Paul C.

AU - Murphy, Declan G.

AU - Bristow, Robert G.

AU - Risbridger, Gail P.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - A key challenge in the management of localized prostate cancer is the identification of men with a high likelihood of progression to an advanced, incurable stage. Patients who harbour germline BRCA2 mutations have worse clinical outcomes than noncarriers when treated with surgery or radiotherapy. Insights from different disciplines have improved our understanding of why patients with BRCA2-mutant tumours have a high likelihood of failing on conventional management after diagnosis. Treatment-naive BRCA2-mutant tumours are defined by aggressive clinical and molecular features early in the disease course, and the genomic landscape of these BRCA2-mutant tumours is characterized by a unique molecular profile and higher genomic instability than noncarrier tumours. Moreover, BRCA2-mutant tumours commonly show the concurrent presence of the intraductal carcinoma of the prostate (IDCP) pathology, a poor prognostic indicator. Subclonal analyses have revealed that IDCP and invasive adenocarcinoma in BRCA2-mutant tumours can arise from the same ancestral clone, implying that a temporal evolutionary trajectory exists. Finally, functional studies have shown that BRCA2-mutant tumours can harbour a subpopulation of cancer cells that can tolerate castration de novo, enabling the tumour to evade androgen deprivation therapy. Importantly, future challenges remain regarding how to best model the biology underpinning this aggressive phenotype and translate these findings to improve clinical outcomes.

AB - A key challenge in the management of localized prostate cancer is the identification of men with a high likelihood of progression to an advanced, incurable stage. Patients who harbour germline BRCA2 mutations have worse clinical outcomes than noncarriers when treated with surgery or radiotherapy. Insights from different disciplines have improved our understanding of why patients with BRCA2-mutant tumours have a high likelihood of failing on conventional management after diagnosis. Treatment-naive BRCA2-mutant tumours are defined by aggressive clinical and molecular features early in the disease course, and the genomic landscape of these BRCA2-mutant tumours is characterized by a unique molecular profile and higher genomic instability than noncarrier tumours. Moreover, BRCA2-mutant tumours commonly show the concurrent presence of the intraductal carcinoma of the prostate (IDCP) pathology, a poor prognostic indicator. Subclonal analyses have revealed that IDCP and invasive adenocarcinoma in BRCA2-mutant tumours can arise from the same ancestral clone, implying that a temporal evolutionary trajectory exists. Finally, functional studies have shown that BRCA2-mutant tumours can harbour a subpopulation of cancer cells that can tolerate castration de novo, enabling the tumour to evade androgen deprivation therapy. Importantly, future challenges remain regarding how to best model the biology underpinning this aggressive phenotype and translate these findings to improve clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85062154262&partnerID=8YFLogxK

U2 - 10.1038/s41585-019-0164-8

DO - 10.1038/s41585-019-0164-8

M3 - Review Article

VL - 16

SP - 281

EP - 290

JO - Nature Clinical Practice Urology

JF - Nature Clinical Practice Urology

SN - 1759-4812

IS - 5

ER -

Taylor RA, Fraser M, Rebello RJ, Boutros PC, Murphy DG, Bristow RG et al. The influence of BRCA2 mutation on localized prostate cancer. Nature Reviews Urology. 2019 May 1;16(5):281-290. https://doi.org/10.1038/s41585-019-0164-8